1043875-02-0

Upstream product

• 1043875-00-8 C₁₂H₇BrN₂OS 

Downstream Products

• 1043875-03-1 C₁₈H₁₁BrN₂OS 
• 1043929-16-3 3-fluoro-4-[2-(3-bromo-phenyl)-thieno[3,2-d]pyrimidin-4-yloxy]-benzonitrile 
• 1043929-15-2 C₁₉H₁₀BrN₃OS 

Relevant academic research and scientific papers

BICYCLIC DERIVATIVES AS EP4 AGONISTS

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein A represents phenyl or cyclohexyl; ring E represents a partially saturated or aromatic 5- membered heterocycle wherein the dotted lines represent an optional double bond and wherein B, C and D each independently represent CH 2, CH, N, NH, S or O and F represents N or C, provided that the 5-membered ring contains 1, 2 or 3 heteroatoms; X represents a direct bond or C 1-4alkanediyl; Y represents N or CH; R1 represents hydrogen or fluoro; R2 represents hydrogen, halo, cyano, C 1-6alkyl, C 1-6alkyloxy, C 1-6alkylcarbonyl or C1-6alkylcarbonylamino; R3 represents hydrogen, halo, C 1-6alkyl, C 1-6alkyloxy, cyano, nitro, amino or mono-or di(C 1- 6alkyl)amino; n represents an integer of value 1, 2 or 3; provided that R3 may onlybe other than hydrogen if at least one of R1 or R2 is other than hydrogen; and provided the compound is other than 4-(4-methylphenoxy)-2-phenyl-thieno- [3,2-d]pyrimidine; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatmentofa disease by activating the EP4 receptor.

BICYCLIC DERIVATIVES AS EP4 AGONISTS

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein ring E represents a partiallysaturated or aromatic 5-membered heterocycle wherein the dotted lines represent an optional double bond and wherein B, C and D each independently represents CH 2, CH, N, NH, S or O and F represents N or C, provided that the 5-membered ring contains 1, 2 or 3 heteroatoms; X represents a direct bond or C 1-4alkanediyl; Y represents N or CH; R1 represents hydrogen or fluoro; R2 represents hydrogen, halo, cyano, C 1-6alkyl, C 1-6alkyloxy, C 1-6alkylcarbonyl or C 1-6alkylcarbonylamino; R3 represents hydrogen, halo, C 1-6alkyl, C 1-6alkyloxy, cyano, nitro, amino or mono-or di(C 1-6alkyl)amino; R4 represents halo; hydroxyl; carboxyl; optionallysubstituted C 1-6alkyl; polyhaloC 1-6alkyl; C 1-6alkyloxycarbonyl; polyhaloC 1-6alkyloxy; optionallysubstituted C 2-6alkenyl; cyano; nitro; NR10 R11; C 1-6alkylthio; optionally substituted C 1-6alkyloxy; or two adjacent R4 substituents may be taken together; n represents an integer of value 1, 2 or 3; m represents aninteger of value 1, 2 or 3; provided that R3 may onlybe other than hydrogen if at least one of R1 or R2 is other than hydrogen; and provided that2,6- bis(1,1-dimethylethyl)-4-[6-(2-phenylethoxy)-1H-purin-2-yl]-phenol is not included; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a disease by activating the EP4 receptor.